--- Connecting LPs & GPs worldwide
--- Connecting LPs & GPs worldwide
German therapeutic antibody developer Affimed has raised €20m in a series C funding round. The fundraising was led by existing investors Aeris Capital, BioMedInvest, LSP Life Sciences Partners, Novo Nordisk and Orbimed, although existing investors may be joining the round at a later date, according to the company.
In order to view premium content you need to be a Premium Subscriber. You can subscribe now to access premium online content.
Become a Premium SubscriberIf you are already a AltAssets subscriber please log in below.
